8-K: Certara Announces $100 Million Share Repurchase Program and Preliminary Q1 2025 Financial Results

Certara, Inc. announces a $100 million share repurchase authorization and preliminary Q1 2025 financial results, showing revenue growth and reiterating full-year guidance.

Summary

• Certara, Inc. announced a $100 million share repurchase program authorized by its Board of Directors.
• The company also released preliminary financial information for the first quarter of 2025, ended March 31, 2025.
• Revenue for Q1 2025 is expected to be $106.0 million, a 10% increase compared to $96.7 million in Q1 2024.
• Software revenue is expected to be $46.4 million, an 18% increase compared to $39.3 million in Q1 2024.
• Services revenue is expected to be $59.6 million, a 4% increase compared to $57.3 million in Q1 2024.
• Bookings are expected to be $118.0 million, a 12% increase compared to $105.8 million in Q1 2024.
• Software bookings are expected to be $40.6 million, a 22% increase compared to $33.1 million in Q1 2024.
• Services bookings are expected to be $77.4 million, a 7% increase compared to $72.7 million in Q1 2024.
• Preliminary revenue and bookings include Chemaxon revenue of $5.9 million and bookings of $4.9 million.
• Adjusted EBITDA is expected to be in the range of $33-$35 million, a 13-20% increase compared to $29.1 million in Q1 2024.
• Certara is reiterating its full-year 2025 guidance, with revenue expected to be in the range of $415 million to $425 million.
• The full year adjusted EBITDA margin is expected to be in the range of 30-32%.
• Full year adjusted diluted earnings per share is expected to be in the range of $0.42 $0.46.
• Fully diluted shares are expected to be in the range of 162 million to 164 million.
• Arsenal Capital Partners has agreed to a one-year lock-up on the sale of shares acquired from EQT in a December 2022 transaction.

Sentiment

Score: 8

Explanation: The announcement is positive due to strong Q1 performance, a share repurchase program, and reiterated full-year guidance. The lock-up agreement from Arsenal Capital Partners further boosts confidence.

Positives

• The $100 million share repurchase program indicates confidence in the company's financial position and future prospects.
• Strong revenue growth in Q1 2025, particularly in software revenue, demonstrates increasing demand for Certara's products and services.
• The increase in bookings suggests continued growth momentum.
• The reiterated full-year 2025 guidance provides reassurance to investors about the company's performance expectations.
• Arsenal Capital Partners' one-year lock-up agreement signals their long-term commitment to Certara.

Negatives

• The preliminary nature of the Q1 2025 financial results means they are subject to change and may differ materially from the final results.
• The strategic review of the regulatory services business introduces uncertainty, although discussions are ongoing.

Risks

• The preliminary financial results are unaudited and subject to change, which could materially impact the final results.
• The company's forward-looking statements are subject to various risks and uncertainties, including market competition, regulatory changes, and economic conditions.
• The strategic review of the regulatory services business could lead to potential disruptions or changes in the company's operations.

Future Outlook

Certara is reiterating its full-year 2025 guidance, expecting revenue between $415 million and $425 million, an adjusted EBITDA margin between 30-32%, and adjusted diluted earnings per share between $0.42 and $0.46.

Management Comments

• 'We are pleased with our first quarter performance, driven by strong commercial execution and demand for our software and services,' said William F. Feehery, Chief Executive Officer.
• 'We are committed to creating shareholder value over the long term at Certara.'

Industry Context

Certara's focus on model-informed drug development aligns with the industry's increasing adoption of technology and data-driven approaches to accelerate drug discovery and development. The share repurchase program could be seen as a way to return value to shareholders amidst a competitive landscape.

Comparison to Industry Standards

• Certara's revenue growth of 10% in Q1 2025 is solid, but needs to be compared to other biosimulation and drug development service companies like Simulations Plus or Schrödinger to assess its relative performance.
• The adjusted EBITDA margin guidance of 30-32% is strong, suggesting efficient operations, but should be benchmarked against peers to determine if it's a leader or laggard.
• The $100 million share repurchase program is a positive sign, but its impact on shareholder value depends on the execution and the company's stock valuation.

Stakeholder Impact

• Shareholders will benefit from the share repurchase program and the potential for increased stock value.
• Employees may be positively impacted by the company's strong performance and continued investment in R&D.
• Customers will benefit from Certara's continued investment in its platform and solutions.
• The lock-up agreement from Arsenal Capital Partners provides stability and confidence to stakeholders.

Next Steps

• Certara will host a conference call on May 5, 2025, to discuss its first quarter 2025 financial results.
• The company will continue to pursue a strategic evaluation of the regulatory services business.
• The company may repurchase shares of its common stock through open market purchases or privately negotiated transactions.

Key Dates

Keywords

share repurchase, financial results, revenue, bookings, EBITDA, guidance, lock-up, Certara, Arsenal Capital, pharmaceutical, biosimulation